Stage IIIC Cutaneous Melanoma AJCC v7 Terminated Phase 2 Trials for Regorafenib (DB08896)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02587650Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTreatment